111 related articles for article (PubMed ID: 9515187)
1. Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine.
Danesi R; Falcone A; Conte PF; Del Tacca M
Clin Pharmacokinet; 1998 Feb; 34(2):173-80. PubMed ID: 9515187
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
Marchbanks K; Dudley MN; Posner MR; Darnowski J
Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
[TBL] [Abstract][Full Text] [Related]
3. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial.
Posner MR; Darnowski JW; Weitberg AB; Dudley MN; Corvese D; Cummings FJ; Clark J; Murray C; Clendennin N; Bigley J
Cancer; 1992 Dec; 70(12):2929-34. PubMed ID: 1451076
[TBL] [Abstract][Full Text] [Related]
5. Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study.
Posner MR; Darnowski JW; Calabresi P; Brunetti I; Corvese D; Curt G; Cummings FJ; Clark J; Browne MJ; Beitz J
J Natl Cancer Inst; 1990 Nov; 82(21):1710-4. PubMed ID: 2231760
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Arkenau HT; Rettig K; Porschen R
Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of zidovudine administered by continuous infusion in children.
Balis FM; Pizzo PA; Murphy RF; Eddy J; Jarosinski PF; Falloon J; Broder S; Poplack DG
Ann Intern Med; 1989 Feb; 110(4):279-85. PubMed ID: 2643914
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.
Balis FM; Pizzo PA; Eddy J; Wilfert C; McKinney R; Scott G; Murphy RF; Jarosinski PF; Falloon J; Poplack DG
J Pediatr; 1989 May; 114(5):880-4. PubMed ID: 2715903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
